We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Watson Cited for Misleading Ferrlecit Promotions
Watson Cited for Misleading Ferrlecit Promotions
May 13, 2005
FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) has cited two journal advertisements circulated by Watson Pharmaceuticals for containing misleading information about the firm’s anemia treatment Ferrlecit.